1. Towards a global plan to fight against bioterrorism in synergy with Russian Federation Novosibirsk 2004-09

2. bioterrorism = a worldwide threat the threat of re-emergent and new emergent diseases

3. Partnership with Russian Federation = Great opportunity: - high-level scientists - expertise - high-level containment facilities

4. Many initiatives…in order to fight against bioterrorism and re-emergent and new emergent diseases, and some of them in the scope the G8  Need of coordination an effective and common synergy with Russian Federation an overview of the research programs and their implementation

5. an international tool of coordination in order to increase the efficiency of our common fight against terrorism in synergy with Russian Federation = a 3-steps master plan : - before - during - after = a global response and preparedness plan against bioterrorism and re-emergent and new emergent diseases

6.  Programs of the partnership in synergy with Russian Federation PREPAREDNESSCRISIS MANAGEMENT REHABILITATION Development of detection tools (diagnostic + environmental) Development of prophylactic means (vaccines,…) + therapeutic means (novel antibacterial and antiviral) + immunotherapy Development* of animal models for toxicological and pharmacological studies Stockpiles of drugs and vaccines Stock of environmental kits of detection Stock of diagnostic kits of detection development of detection tools for circumscription of contamination (perhaps the same ones than those used in preparedness step) Development of new decontamination means

7.  Programs of the partnership in synergy with Russian Federation  IN THE STEP OF PREPAREDNESS Development* of animal models for toxicological and pharmacological studies *Requirements for these developments: It is necessary to improve and/or develop referential and recognized animal models by the national competent authorities in order to permit the registration of marketing authorizations of new drugs. These models involve use of tools as pharmaco and toxico genomics, proteomics, metabonomics.

8. WHY DO WE NEED DEVELOPMENT OF VALIDATED ANIMAL MODELS ? LIFE OF DRUG PRODUCTS ? ? REGULATORY AGENCIES PHASES Human Biomarkers Animal Biomarkers

9. Programs of the partnership in synergy with Russian Federation These animal models should be evaluated at the international level  By each regional Regulatory Agencies and Pharmaceutical industry representatives  According OECD and ICH guidelines  Validated by ICH, ILSI HESI and WHO organisations

10. Preliminary requirement for Russian Federation and also other partners GLP, GCP, GMP and ICH Recommendations facilities and training Create, or identify, a department, or an agency, inside the Russian Health Ministry in order to perform inspections and audits for non-clinical and clinical studies and to deliver conformity certificates to international standards in order to achieve R&D (to take into account the results coming from search) in view of pharmaceutical production for sale on the international market strict quality control standards must be observed such as Good Manufacturing Practices, Good Laboratory Practices, ICH Recommendations. Such essential regulations are now being introduced in Russian Federation

11.  Programs of the partnership in synergy with Russian Federation  IN THE STEP OF PREPAREDNESS Development of detection tools (diagnostic + environmental) *Requirements for these developments : There is a lack of detection tools for many existing and emerging pathogenes.

12.  Programs of the partnership in synergy with Russian Federation  IN THE STEP OF PREPAREDNESS Development of therapeutic means (novel antibacterial and antiviral) *Requirements for these developments : There is a great need in this field because of the unefficacy of the existing drug product.

13.  Programs of the partnership in synergy with Russian Federation For each topic of this master plan, it would be fine if a special dossier (file) should be written by the country responsible for the action, with indication of:  who does what,  with whom  what kind of complementary action  possible other cooperation  ….

14.  Members and observers of OECD Defined, reinforced and applied the future rules of biosecurity for Biological Resource Centres - BRC’s - (definition of operating and exchanges rules for a global network of BRC’s in progress, under the aegis of OECD) A Biological Resource Centre is a center which holds and supplies biological material with authentification and long-term sustainability. It can keep highly pathogen strains

15.  Each country, that is to say: nationally  In preparedness step : Domestic biosecurity legislation and law reinforcement From now on, apply quality management systems as a powerful tool for biosecurity (global traceability of staff, materials, operations, storage,….) in Biological Resource Centres  In crisis management step: Governmental responses plans implementation

16.  Towards an international synergy: all together  In preparedness step: –Reinforcement of the international cooperation and criminalization against trafficking and fraudulent use of pathogens and toxins: towards an international traceability and cooperation in order to fight against fraudulent use of pathogens as the dispositions of the UN narcotic psychotropes convention ? –Development and reinforcement of epidemiological network and global system alert under the aegis of WHO, OIE, FAO (diagnostic detection tool, training,…)

17.  Towards an international synergy: all together  In crisis management step: Harmonization of national, regional and international response plans, for notably interoperability, in connection with WHO, OIE, FAO and according to WHO, OIE, FAO policies Reinforcement of the global epidemiological network

18. Thank you for your attention and your… patience! Dr Hervé Raoul + 33 1 69 26 56 99 Dr Hervé Raoul + 33 1 69 26 56 99herve.raoul@cea.fr Dr Dominique Masset + 33 1 55 87 35 84 dominique.masset@afssaps.sante.fr Dr Isabelle Daoust-Maleval, + 33 1 71 75 80 75 isabelle.daoust-maleval@sgdn.pm.gouv.fr isabelle.daoust-maleval@sgdn.pm.gouv.fr